elagolix

(R)-Elagolix (NBI-56418) is a short-acting, nonpeptide, GnRH antagonist with an IC50 and Ki of 0.25 and 3.7 nM, respectively. administered orally, that unlike injectable depot GnRH agonists and antagonists, produces a dose-dependent suppression of ovarian estrogen production, that is, from partial suppression at lower doses to full suppression at higher doses.

Elagolix is an orally active, highly effective, selective non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRH receptor) with a dissociation constant (KD) of 54 pM, as well as an NFAT inhibitor, and is utilized in researching endometriosis-related pain.

Elagolix sodium (NBI-56418 sodium) is a GnRH receptor (GnRHR) antagonist ( IC50 and Ki of 0.25 and 3.7 nM, respectively).

Elagolix-d9 is the deuterium-labeled form of Elagolix. Elagolix sodium acts as a highly potent, selective, and orally active, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRH receptor) with a dissociation constant (KD) of 54 pM. It also functions as an NFAT inhibitor and is utilized in research focusing on pain related to endometriosis.